Exposure to toxic chemicals, especially chemotherapeutic drugs, may induce several DNA lesions, including DNA interstrand crosslinks. These crosslinks are considered toxic lesions to the dividing cells since they can ...Exposure to toxic chemicals, especially chemotherapeutic drugs, may induce several DNA lesions, including DNA interstrand crosslinks. These crosslinks are considered toxic lesions to the dividing cells since they can induce mutations, chromosomal rearrangements, and cell death. Many DNA interstrand crosslinks lesions can be generated by platinum-based chemotherapeutic agents. Satraplatin is a novel orally administered platinum-based chemotherapeutic agent. In the present study, we investigated DNA interstrand crosslinks lesions induced by oxaliplatin and satraplatin in lymphocytes obtained from colorectal cancer patients and healthy volunteers. Satraplatin demonstrated an increase in interstrand crosslinks in a dose-dependent manner in the Comet assay (p in vitro. Here, to the best of our knowledge we report for the first time evidence of DNA double strand breaks formation as a possible molecular mechanism of action for satraplatin.展开更多
Fanconi anemia(FA)is an autosomal or X-linked recessive disorder characterized by chromosomal instability,bone marrow failure,cancer susceptibility,and a profound sensitivity to agents that produce DNA interstrand cro...Fanconi anemia(FA)is an autosomal or X-linked recessive disorder characterized by chromosomal instability,bone marrow failure,cancer susceptibility,and a profound sensitivity to agents that produce DNA interstrand cross-link(ICL).To date,15 genes have been identified that,when mutated,result in FA or an FA-like syndrome.It is believed that cellular resistance to DNA interstrand cross-linking agents requires all 15 FA or FAlike proteins.Here,we review our current understanding of how these FA proteins participate in ICL repair and discuss the molecular mechanisms that regulate the FA pathway to maintain genome stability.展开更多
文摘Exposure to toxic chemicals, especially chemotherapeutic drugs, may induce several DNA lesions, including DNA interstrand crosslinks. These crosslinks are considered toxic lesions to the dividing cells since they can induce mutations, chromosomal rearrangements, and cell death. Many DNA interstrand crosslinks lesions can be generated by platinum-based chemotherapeutic agents. Satraplatin is a novel orally administered platinum-based chemotherapeutic agent. In the present study, we investigated DNA interstrand crosslinks lesions induced by oxaliplatin and satraplatin in lymphocytes obtained from colorectal cancer patients and healthy volunteers. Satraplatin demonstrated an increase in interstrand crosslinks in a dose-dependent manner in the Comet assay (p in vitro. Here, to the best of our knowledge we report for the first time evidence of DNA double strand breaks formation as a possible molecular mechanism of action for satraplatin.
基金supported in part by grants from the China’s Fundamental Research Funds for the Central Universitiesthe National Natural Science Foundation of China(Grant No.31071243)the Natural Science Foundation of Zhejiang Province(Grant R2110569)(to J.H.).
文摘Fanconi anemia(FA)is an autosomal or X-linked recessive disorder characterized by chromosomal instability,bone marrow failure,cancer susceptibility,and a profound sensitivity to agents that produce DNA interstrand cross-link(ICL).To date,15 genes have been identified that,when mutated,result in FA or an FA-like syndrome.It is believed that cellular resistance to DNA interstrand cross-linking agents requires all 15 FA or FAlike proteins.Here,we review our current understanding of how these FA proteins participate in ICL repair and discuss the molecular mechanisms that regulate the FA pathway to maintain genome stability.
